Despite decades of research on the bacterial ribosome, the ribosomal exit tunnel is still poorly understood. Although it has been suggested that the exit tunnel is simply a convenient route of egress for the nascent chain, specific protein sequences serve to slow the rate of translation, suggesting some degree of interaction between the nascent peptide chain and the exit tunnel. To understand how the ribosome interacts with nascent peptide sequences, we synthesized and characterized a novel class of probe molecules. These peptide-macrolide (or "peptolide") conjugates were designed to present unique peptide sequences to the exit tunnel. Biochemical and X-ray structural analyses of the interactions between these probes and the ribosome reveal interesting insights about the exit tunnel. Using translation inhibition and RNA structure probing assays, we find the exit tunnel has a relaxed preference for the directionality (N → C or C → N orientation) of the nascent peptides. Moreover, the X-ray crystal structure of one peptolide derived from a positively charged, reverse Nuclear Localization Sequence peptide, bound to the 70S bacterial ribosome, reveals that the macrolide ring of the peptolide binds in the same position as other macrolides. However, the peptide tail folds over the macrolide ring, oriented toward the peptidyl transferase center and interacting in a novel manner with 23S rRNA residue C2442 and His69 of ribosomal protein L4. These data suggest that these peptolides are viable probes for interrogating nascent peptide-exit tunnel interaction.
Despite decades of research on the bacterial ribosome, the ribosomal exit tunnel is still poorly understood. Although it has been suggested that the exit tunnel is simply a convenient route of egress for the nascent chain, specific protein sequences serve to slow the rate of translation, suggesting some degree of interaction between the nascent peptide chain and the exit tunnel. To understand how the ribosome interacts with nascent peptide sequences, we synthesized and characterized a novel class of probe molecules. These peptide-macrolide (or "peptolide") conjugates were designed to present unique peptide sequences to the exit tunnel. Biochemical and X-ray structural analyses of the interactions between these probes and the ribosome reveal interesting insights about the exit tunnel. Using translation inhibition and RNA structure probing assays, we find the exit tunnel has a relaxed preference for the directionality (N → C or C → N orientation) of the nascent peptides. Moreover, the X-ray crystal structure of one peptolide derived from a positively charged, reverse Nuclear Localization Sequence peptide, bound to the 70S bacterial ribosome, reveals that the macrolide ring of the peptolide binds in the same position as other macrolides. However, the peptide tail folds over the macrolide ring, oriented toward the peptidyl transferase center and interacting in a novel manner with 23S rRNA residue C2442 and His69 of ribosomal protein L4. These data suggest that these peptolides are viable probes for interrogating nascent peptide-exit tunnel interaction.
The ribosome,
through well-choreographed
processes, translates genetically encoded messages on mRNAs to polypeptides.
While structural and biochemical studies of prokaryotic 70S ribosome
have enhanced our understanding of the role many of these components
play during translation,[1−6] little is understood about the ribosomal peptide exit tunnel. During
elongation of the nascent peptide, the growing peptide chain extends
from the peptidyl transferase center (PTC) to the backside of the
ribosome through the peptide exit tunnel, an 80 Å long, 20 Å
wide exit tunnel that extends across the large subunit of the ribosome
from the base of the PTC and opens at the back of the subunit.[4,7,8] The role of the peptide exit tunnel
is primarily to act as a route of egress for the nascent peptide;[4,9,10] however, in some cases, specific
interactions between the nascent peptide and the exit tunnel walls
have been shown to alter translational regulation.[9,11−13] Currently, it is not well understood how the ribosome
could distinguish and respond to specific peptide sequences while
facilitating an unhindered passage of the vast majority of peptides
through the peptide exit tunnel.Efforts aimed at mapping the
paths of the nascent peptide through
the ribosome have focused mainly on trapping sequence-specific peptides
known to interact directly with the exit tunnel.[11,14] Specifically, fluorescence resonance energy transfer (FRET),[15] molecular-dynamics simulation,[11] and cross-linking experiments[16] have furnished biochemical insights into the interactions between
a 17 amino acid motif near the C terminus of SecM and the components
of the Escherichia coli (E. coli) ribosome exit tunnel, which results in translation arrest. Single
particle cryo-EM reconstructions have revealed the presence of a relay
mechanism involving direct interactions between the nascent peptide
and ribosomal exit tunnel resulting in the ribosome stalling during
translation of both the ErmBL leader peptide in the presence of erythromycin[17] and the tnaC leader gene.[14] Moreover, analysis of primer extension inhibition
has led to the postulation of similar peptide-dependent ribosome stalling
relay mechanisms at the regulatory cistron of the antibiotic resistance
gene ermA.[18] While these
experiments provide evidence that distinct peptides interact with
the exit tunnel, they illustrate the importance of designing molecular
probes, which can precisely position any peptide sequence within a
defined region of the peptide exit tunnel.Recently, analogs
of 16-membered macrolidestylosin, desmycosin,
and 5-O-mycominosyltylonolide incorporating esters of amino acids,
di- and tripeptides have been shown to engage the exit tunnel through
distinct interactions with ribosomal components, presumably using
their amino acid and peptide moieties.[19,20] Specifically,
molecular dynamics simulations suggest that the N-acylglycyl moiety
of the aminoacylated 5-O-mycominosyl-tylonolide derivative could be
positioned to form hydrogen bonds with 23S rRNA A752 and Lys 90 of
ribosomal protein L22. These hydrogen bonds could potentially disrupt
the essential A752:U2609 base pair, which has previously been shown
to play a role in both peptide stalling and macrolide antibiotic interactions.[20,22,25] However, the peptide moieties
of these conjugates are short and are expected to interrogate only
a short segment of the exit tunnel, particularly the tunnel entrance.Toward the development of robust molecular probes for exploring
the passage of nascent peptide through the exit tunnel, we designed
oligopeptides covalently linked to a ketolide analog, which we term
“peptolides” (Figure 1). Ketolides
are a class of small molecule antibiotics, collectively known as macrolides,
which inhibit prokaryotic translation by sterically blocking the exit
tunnel near the PTC.[21] As an inspiration
for the design of these peptolide probes, we looked at telithromycin
(TEL), a unique ketolide with a flexible alkyl-aryl arm (Figure 1a). X-ray crystallographic studies have shown that
the alkyl-aryl arm of TEL can adopt three distinct conformations:
extending toward the A752:U2609 base pair (E. coli and T. thermophilus), down the peptide exit tunnel
in the same direction as a nascent chain (D. radiodurans), or folded back over the macrolide ring in the direction of the
PTC (H. marismortui) (Figure 1b).[22−25]
Figure 1
Design
of peptide–ketolide (peptolide) compounds. (a) Structures
of representative ketolides: telithromycin (TEL), cethromycin, and
TE-802. (b) Binding of TEL to the 50S subunit of the ribosome. (Left)
An overlay of TEL shows alternate positioning of the alkyl-aryl arm
when bound to T. thermophilus (yellow, PDB ID 3OI3), E. coli (beige, PDB ID 3OAT), H. marismortui (green, PDB ID 1YIJ), and D.
radiodurans (cyan, PDB ID 1P9X). TEL binds to the 50S exit tunnel in
between the PTC, represented by the P-site and A-site tRNA, and the
constriction site in the exit tunnel formed by 50S ribosomal protein
L4 (blue) and L22 (red). (Right) In each of the macrolide structures,
the desosamine sugar hydrogen bonds with A2058 stabilizing the macrolactone
ring. The alkyl-aryl arm stacks against the A752:U2609 base pair in T. thermophilus (yellow) and E. coli (beige).
In the absence of the A752:U2609, the alkyl-aryl arm hydrogen bonds
to U2609 in H. marismortui (green) or extends down
the exit tunnel in D. radiodurans (cyan). There is
a 135° orientation between the left and right panel. (c) General
structure of peptolide derived from TEL. Changes to the TEL template
to yield the target peptolide probes are highlighted in red with ···XXXX···
indicating polypeptide containing any combination of amino acids of
interest.
Design
of peptide–ketolide (peptolide) compounds. (a) Structures
of representative ketolides: telithromycin (TEL), cethromycin, and
TE-802. (b) Binding of TEL to the 50S subunit of the ribosome. (Left)
An overlay of TEL shows alternate positioning of the alkyl-aryl arm
when bound to T. thermophilus (yellow, PDB ID 3OI3), E. coli (beige, PDB ID 3OAT), H. marismortui (green, PDB ID 1YIJ), and D.
radiodurans (cyan, PDB ID 1P9X). TEL binds to the 50S exit tunnel in
between the PTC, represented by the P-site and A-site tRNA, and the
constriction site in the exit tunnel formed by 50S ribosomal protein
L4 (blue) and L22 (red). (Right) In each of the macrolide structures,
the desosamine sugarhydrogen bonds with A2058 stabilizing the macrolactone
ring. The alkyl-aryl arm stacks against the A752:U2609 base pair in T. thermophilus (yellow) and E. coli (beige).
In the absence of the A752:U2609, the alkyl-aryl arm hydrogen bonds
to U2609 in H. marismortui (green) or extends down
the exit tunnel in D. radiodurans (cyan). There is
a 135° orientation between the left and right panel. (c) General
structure of peptolide derived from TEL. Changes to the TEL template
to yield the target peptolide probes are highlighted in red with ···XXXX···
indicating polypeptide containing any combination of amino acids of
interest.In each of the structures, the
alkyl-aryl arm is engaged in different
stabilizing interactions. In E. coli and T. thermophilus, the arm is stabilized by stacking against
the rRNA A752:U2609 base pair. In H. marismortui,
which lacks the A752:U2609 base pair, the arm is stabilized by a hydrogen
bond with the O2′ of U2609 while in D. radiodurans, the arm extends down the exit tunnel and is potentially engaged
in van der Waals interactions with the 23S rRNA.[6] As long as these crucial interactions remain intact, it
is feasible that the arm could be modified beyond the aryl group and
allow new ligands to be added while preserving the ketolide binding
mode. The path of travel through the ribosome by the modified TEL
flexible arm could be influenced by the identity of the substituents
on its aryl moiety. For the proposed peptolides, it is conceivable
that the identity (and/or sequence) of the peptide attached to the
modified alkyl-aryl arm could dictate the placement of the peptides
within the ribosome through preferential adoption of one of the three
distinct alkyl-aryl arm positions (Figure 1b).[22−26]We report herein the design, synthesis, and characterization
of
a set of peptide–ketolide (peptolide) compounds. We demonstrate
that these peptolides inhibit translation in cell-free prokaryotic
and eukaryotic systems. RNA footprinting experiments suggest that
the peptolide macrocycle moiety binds to the parent macrolide binding
site on the E. coli ribosome with affinity that is
dependent on the overall charge of the peptide tail. Lastly, we solved
the X-ray crystal structure of one peptolide bound to the 70S. Our
combined data show that the peptolide adopts a conformation with its
peptide tail oriented back toward the PTC and the subunit interface
close to 23S rRNA residue U1963 located between the A and P sites.
Taken together, our results indicate these distinct peptolides could
be useful probes for interrogating nascent peptide-exit tunnel interaction
between the PTC to the L4/L22 constriction site. This approach could
provide a general means for a precise placement of peptides into both
the exit tunnel and path from the PTC to the tunnel entrance.
Results
and Discussion
Peptolide Design and Synthesis
We
designed a series
of TEL-derived peptolides that have the phenyl and the imidazolyl
groups substituted by peptides and 1,2,3-triazole ring, respectively
(Figure 1c). The latter modification, achieved
through the Cu(I) promoted cycloaddition reaction of crucial azido-ketolides 7a,b (Scheme 1) and appropriately protected terminal alkyne modified peptides,
is essential to promote compound synthetic tractability.[27,28] These peptolides differ in the (1) direction of attachment (amino
or carboxy terminus), (2) number of the amino acids in the peptide
moiety, and (3) composition of amino acid of the peptide moiety (Scheme 2). These variations are incorporated into the design
in order to investigate the influence of both the nature of individual
amino acids and the orientation of the peptide chain within the exit
tunnel with respect to the affinity of the peptolides for the ribosome.
Reagents and conditions:
(a) 7a or 7b, CuI, THF, diisopropylethylamine
(DIPEA),
room temperature; (b) TFA/TIPS/phenol, room temperature. The structures
of deprotected alkyne peptide 13–16 are in the Supporting Information (SI), Figure S1.
The requisite azido-ketolides intermediates 7a,b were obtained from clarithromycin 1 adapting literature produres.[27,29] Briefly, selective
hydrolysis of the cladinose sugar of clarithromycin 1 in dilute HCl afforded descladinose compound 2 whose
2′-OH group was selectively acylated by treating it with acetic
anhydride (Ac2O) in acetone at 40 °C for 24–48
h to give compound 3 in quantitative yield. Corey–Kim
oxidation of the 3-OH group of 3 gave 3-keto compound 4, which was subsequently converted to 12-carbamoylimidazolideketolide 5 by treatment with excess carbonyldiimidazole (CDI) and sodium
hexamethyldisilazide (NaHMDS) in a mixture of tetrahydrofuran/dimethylformamide
(THF/DMF). Compound 5 was converted to the desired intermediates 7a,b through a two-step-one-pot
process involving a displacement of the imidazole group followed by
an intramolecular Michael addition by azido amine 6a,b to give acetylated 11,12-cyclic carbamate
analogs.[30] Subsequent methanolysis of the
carbamate analogs afforded the desired azido-ketolide 7a,b in 60–90% yield (Scheme 1). The transformation of azido-ketolide intermediates 7a,b into the desired peptolides 12a–h involved Cu (I) catalyzed cycloaddition
reaction[31] between 7a,b and appropriately protected peptides 8–11 bearing terminal alkynes followed
by the removal of the protecting groups by treatment of the fully
protected peptolides with trifluoroacetic acid/triisopropylsilane/phenol
at room temperature (Scheme 2).[32]
Reagents and conditions:
(a) 7a or 7b, CuI, THF, diisopropylethylamine
(DIPEA),
room temperature; (b) TFA/TIPS/phenol, room temperature. The structures
of deprotected alkyne peptide 13–16 are in the Supporting Information (SI), Figure S1.
Translation Inhibition
and Footprinting Studies
To
characterize the effects of the peptolide probes on ribosomal function,
we analyzed the ability of the peptolides to inhibit prokaryotic and
eukaryotic translation. The prokaryotic assay we used is based on
the whole cell extract from E. coli, while the eukaryotic
assay is comprised of rabbit reticulocyte whole cell lysate (RRL).
Both assays utilize a luciferase based reporter whereby protein expression
is monitored by the amount of luciferase protein product.[33,34] KetolideTE-802 and clarithromycin 1 were used as positive
controls. The fully deprotected, unattached peptides 13–16 were also tested to parse out the contribution
of the peptolide peptide moieties on translation inhibition activity
(Table 1).
Table 1
IC50 Cell
Free Assays Translation
Inhibition Activity of Peptolides against Prokaryotic and Eukaryotic
Ribosomal Preparationsa
compds.
E.
coli IC50 (μM)
rabbit retic.
IC50 (μM)
12a
1.32 ± 0.08
>250
12b
0.67 ± 0.28
>250
13
>250b
>250
12c
1.86 ± 0.35
>250
12d
1.10 ± 0.22
>250
14
>250b
>250
12e
4.32 ± 0.25
140
12f
2.73 ± 0.82
38
15
>1000c
205
12g
56.00 ± 9.60
>250
12h
7.41 ± 1.20
>250
16
>250b
>250
TE-802
0.52 ± 0.05
>250
clarithromycin 1
0.32 ± 0.12
>250
Luciferase activity was used
as a reporter of translation inhibition in both systems. IC50 values were obtained from an average of three independent experiments.
No inhibition at maximum tested
concentration (250 μM).
Maximum tested concentration increased
4-fold to obtain information about the extent of selectivity over
RRL.
Luciferase activity was used
as a reporter of translation inhibition in both systems. IC50 values were obtained from an average of three independent experiments.No inhibition at maximum tested
concentration (250 μM).Maximum tested concentration increased
4-fold to obtain information about the extent of selectivity over
RRL.We observed that each
of the peptolide probes retained potent prokaryotic
translation inhibition, although the most potent peptolide, 12b, is almost equipotent as TE-802 and 2.0-fold less active
than 1, the positive ketolide and macrolide controls,
respectively. A striking difference in the translation inhibition
activity of these peptolides is evident when comparing the amino acid
composition of their peptides. The overall positive charge of the
amino acid residues of the deprotected peptides decreases as such:
peptides 13 (+6), 14 (+5), 15 (+3), and 16 (zwitterionic) (Supporting
Information, Figure S1). Translation inhibition is strongly
dependent on the net positive charge on the peptide moieties of each
peptolide with 12a–d, peptolides
derived from the most positively charged peptides 13 and 14, being most active, while 12g–h, peptolides derived from zwitterion peptide 16 are the least active. This observation suggests that the positively
charged peptides such as 13 and 14 have
an enhanced affinity for the phosphate backbone of the rRNA, which
lines the exit tunnel. Since the peptide tails alone did not cause
significant translation inhibition, we believe the ketolide macrocyclic
ring of the peptolide acts as an anchor whose affinity for the ribosome
is in turn modulated by the extent of accommodation of the peptide
moieties within the ribosome.The effect of peptide direction
could be evaluated through the
analysis of the translation inhibition activity. Peptides 13 and 14 have net charges of +6 and +5, respectively,
and are derived from nearly identical sequences. When conjugated to
the ketolide macrocycle, the only major distinction between peptolides
derived from 13 and 14 is the direction
of peptide attachment to the ketolide ring, with 13 attached
through the carboxy terminus and 14 through the amino
terminus (Scheme 2). Interestingly, the match
pair peptolides 12a/12c and 12b/12d have nearly indistinguishable translation inhibition
activity (Table 1). This suggests that the
direction in which the peptides travels, N to C or C to N, through
the tunnel does not seem to have much of an effect on the translation
inhibition of the probes or their ability to interact with the exit
tunnel.We could, however, not rule out from this assay the
possibility
of the peptide moieties of these peptolides adopting different conformations
influenced by the flexibility of the alkyl-triazolyl moiety, akin
to what has been structurally observed with TEL (Figure 1b). The consequence of a moderate restriction of the flexibility
of the alkyl-triazolyl moiety becomes apparent when comparing the
translation inhibition potency of peptolides derived from propyl-linked
(n = 1) and butyl-linked (n = 2)
azido-ketolides 7a and 7b, respectively.
For 13 and 14, peptides with the most positive
charge, the effect of reduction of ketolide linker length is negligible
(Table 1, compare match pairs 12a/12b and/or 12c/12d). However,
linker length reduction further exacerbates the compromised affinity
of peptolide derived from a zwitterionic peptide, with approximately
10-fold reduction in translation inhibition activity (Table 1, compare match pairs 12g/12h).The peptolides were evaluated in a eukaryotic translation
system
to assess their selectivity for prokaryotic ribosomes over eukaryotic
ribosomes. As anticipated, the control TE-802 and Clarithromycin are
inactive at 250 μM (Table 1). The majority
of the peptolides and the analogous deprotected peptides were unable
to inhibit eukaryotic translation. However, the unattached deprotected
peptide 15 showed slight translation inhibition with
an IC50 of 205 μM, resulting in only a ∼ 4-fold
selectivity over the prokaryotic ribosome. When conjugated with the
butyl-linked (n = 2) azido-ketolide 7b, the resulting peptolide 12f showed significant inhibition
of eukaryotic translation with an IC50 of 38 μM (Table 1). This suggests there are subtle architectural
differences between the eukaryotic and prokaryote exit tunnels which
allow for more favorable interactions with peptide 15 and its analogous peptolide 12f within the context
of the eukaryotic ribosome.To further characterize the mode
of association of the peptolide
probes with the ribosome, we performed RNA structure probing analysis
of the E. coli 23S rRNA using chemical footprinting
of intact 70S. We employed dimethylsulfate (DMS) and N-cyclohexyl-N′-(2-morpholinoethyl)carbodiimide
(CMCT) as the nucleic acid modifying agents.[35,36] DMS footprinting gel in Figure 2 shows a
clear peptolide footprint at the residue A2058 of the E. coli 23S rRNA. In lanes 5 and 6 are unmodified and DMS-modified rRNAs,
respectively, in the absence of probes. Any differences between these
lanes highlight residues that are available for DMS modification.
Similarly, any differences between lane 6 and lanes 7–16, lanes
containing rRNAs that are DMS-modified after drug or probe binding,
will highlight any sites that have changes in DMS availability. The
reduction in intensity at nucleotide A2058 in the presence of each
peptolide is clear evidence of a drug binding footprint. This is an
expected site of drug interaction as A2058 is known to interact with
the macrolide ring upon binding to the well-defined macrolide binding
pocket of the ribosome.[22−25] Thus, this footprinting result verifies that the
binding target of the macrocycle moieties of the peptolide probes
is indeed the same as the parent macrolide drug.
Figure 2
DMS footprinting
of 23S rRNA. Dideoxy sequencing lanes G, C, A,
and T (lanes 1–4) followed by unmodified rRNA (lane 5), DMS
modified 23S rRNA (lane 6), DMS modified 23S rRNA in the presence
of clarithromycin and 7b intermediate (lanes 7–8,
respectively), 23S rRNA DMS modified in the presence of 12a–h (lanes 9–16, respectively). A representative
complete gel is shown in SI Figure S2.
For nearly
all peptolides, the A2058 band is barely visible except
for 12g, the peptolide derived from the propyl-linked
(n = 1) azido-ketolide 7a and the zwitterionic
peptide 16, which has a relatively more pronounced A2058
band (lane 15). The reduction in peptolide-induced protection from
DMS modification at nucleotide A2058 by peptolide 12g, in comparison to the other peptolides, is indicative of a decreased
binding affinity of peptolide 12g in the macrolide binding
pocket. This decreased binding affinity correlates well with our E. coli translation inhibition study which showed peptolide 12g has the weakest translation inhibition activity (IC50 value of 60 μM, Table 1). DMS
probing of the other key residues within the large subunit did not
reveal strong peptolide-induced protection (data not shown). Importantly,
A752 is protected by TEL presumably due to the placement of the alkyl-aryl
arm into this section of the tunnel.[37] However,
A752 is not protected by any of the peptolides (SI Figure S3) indicating the modified alkyl-aryl arm of the
peptolides is not oriented toward the A752:U2609 base pair.DMS footprinting
of 23S rRNA. Dideoxy sequencing lanes G, C, A,
and T (lanes 1–4) followed by unmodified rRNA (lane 5), DMS
modified 23S rRNA (lane 6), DMS modified 23S rRNA in the presence
of clarithromycin and 7b intermediate (lanes 7–8,
respectively), 23S rRNA DMS modified in the presence of 12a–h (lanes 9–16, respectively). A representative
complete gel is shown in SI Figure S2.CMCT footprinting reveals information
about the binding pocket
of the peptolide peptide moieties within the ribosome (Figure 3). In lanes 6–8, a band corresponding to
U1963 is clearly visible. This residue is thus available to CMCT modification
in the absence and presence of both clarithromycin and the azido-ketolide
intermediate 7b. In marked contrast, U1963 is strongly
protected from modification by CMCT in the presence of all peptolide
probes, evidenced by the near absence of this band in lanes 9–16
(Figure 3, SI Figure
S4).
Figure 3
CMCT footprinting of 23S rRNA. Dideoxy sequencing lanes G, C, A,
and T (lanes 1–4) followed by unmodified rRNA (lane 5), CMCT
modified 23S rRNA (lane 6), CMCT modified 23S rRNA in the presence
of clarithromycin and 7b intermediate (lanes 7 and 8,
respectively), 23S rRNA CMCT modified in the presence of 12a–h (lanes 9–16, respectively).
CMCT footprinting of 23S rRNA. Dideoxy sequencing lanes G, C, A,
and T (lanes 1–4) followed by unmodified rRNA (lane 5), CMCT
modified 23S rRNA (lane 6), CMCT modified 23S rRNA in the presence
of clarithromycin and 7b intermediate (lanes 7 and 8,
respectively), 23S rRNA CMCT modified in the presence of 12a–h (lanes 9–16, respectively).U1963 is part of Helix 71 (H71) located within
domain IV of the
23S which forms part of the front rim of the peptidyl transferase
active site cleft.[4] The CMCT protection
of U1963 suggests these peptolides all adopt a similar binding orientation
such that their peptide moieties mimic the path a nascent peptide
would traverse extending from the PTC to the proximity of the entrance
to the exit tunnel. The lack of protection by 7b shows
the azido-alkyl moiety is not sufficiently long to block access to
U1963. Ribosomal rRNA U1963 is a crucial residue within the overlapping
binding sites of RRF, EF-G, and the P-site tRNA[38] suggesting a plausible mechanism of translation inhibition
by inhibiting the binding of these critical translation components.
Both the N- and C-linked peptolides 12a–d cause indistinguishable protection of U1963, indicating
the tolerance of the exit tunnel for either the biological N →
C or the abiological C → N orientation of nascent peptide.
This raised an interesting prospect that the choice of N →
C as the direction of travel of the nascent peptides through the exit
tunnel may simply be due to the restriction imposed by the peptidyl
transfer chemistry.
Structural Studies of Peptolide 12c Bound to the
70S Ribosome
Previous X-ray crystallographic studies of similar
ketolides, TEL and CEM101, show these macrolides bind to the macrolide
binding pocket in the upper portion of the ribosomal exit tunnel,
adjacent to the L22 and L4 constriction site.[22−25] In order to determine if these
peptolides bind in the same macrolide-binding site with a similar
orientation for the modified alkyl-aryl tail, we cocrystallized the
peptolide 12c, derived from the propyl-linked (n = 1) azido-ketolide 7a and the positively
charged NLS peptide attached at the N-terminal (reverse NLS peptide 14), with T. thermophilus 70S ribosomes programmed
with mRNA, P-site tRNAfMet, and A-site tRNAPhe. The peptolide (1 μM final concentration) was incubated with
programmed ribosome complexes just prior to crystallization. X-ray
diffraction data was collected, processed, and the structure was solved
to 3.6 Å using molecular replacement with a 70S ribosome structure
where the tRNA and mRNA ligands removed (PDB ID codes 2WDG, 2WDH, 2WDI, and 2WDJ).[39] Unbiased Fo–Fc difference electron density maps show clear
and connected density of the ketolide macrocyclic ring and eight of
the 12 residues in the peptide tail except for Lys5 (SI Figure S5).The 70S-peptolide 12c structure
shows the ketolide macrocyclic ring adopts a similar orientation in
the macrolide binding site on the 50S subunit as observed in previous
structures.[22−25] Specifically, the desosamine sugar at position 5 of the ketolide
macrocyclic ring hydrogen bonds with the base of 23S rRNA A2058 and
the surface of this ring forms hydrophobic packing interactions with
the bases of U2611, A2058, and A2059. These results indicate the addition
of the peptide tail does not alter the ketolide macrocyclic ring position
as observed in other crystal structures.Similar to other ketolides,
the peptolides described in this study
also contain a flexible alkyl-aryl arm. Previous crystal structures
have shown three distinct conformations of the alkyl-aryl arm of TEL.
When bound to E. coli or T. thermophilus 70S, the alkyl-aryl arm of TEL packs against the U2609:A752 base
pair.[22,25] In H. marismortui, the
alkyl-aryl arm folds back over the top of the macrolactone ring[24] while in D. radiodurans, the
alkyl-aryl arm extends further down the peptide exit toward the L4/L22
constriction site.[23] This altered conformation
of the alkyl-aryl arm observed in H. marismortui and D. radiodurans has been hypothesized to be a consequence
of the absence of a U2609:A752 base pair.[25]Our 70S-peptolide 12c structure indicates the
alkyl-aryl
arm of the peptolide extends further down the peptide exit tunnel
in a similar conformation as observed with D. radiodurans (Figure 1b, Figure 4, and SI Figure S5). However, despite
the positioning of the alkyl-aryl arm toward the L4/L22 constriction
site, the peptide portion of the peptolide turns and folds back over
the top of the ketolide macrocyclic ring oriented toward the PTC with
its position stabilized through the formation of two new hydrogen
bonds between peptolide residues Lys6 and Lys7 with 23S rRNA C2442
and the side chain of His69 of ribosomal protein L4, respectively
(Figure 4). Since all peptolides contain a
positively charged residue at an analogous position, it is possible
they all interact with C2442 in a similar manner. The electron density
of the peptolide tail is disordered beyond the eighth amino acid of
the attached peptide chain and therefore the last four residues were
not built. While the well-ordered portion of the peptide tail does
not extend past the exit tunnel L4/L22 constriction site, the entire
exit site tunnel is blocked by the peptide tail folding back on top
of the ketolide macrocyclic ring (Figure 4).
Although the peptide tail
is too short to directly interact with U1963 that is protected in
the CMCT footprinting experiments (Figure 3), the peptide tail may cause a rearrangement of the adjacent 23S
rRNA residues in the PTC thereby indirectly resulting in U1962 protection.
Figure 4
Binding
site of peptolide 12c in the 50S subunit of
the ribosome. Similar to TEL, peptolide 12c binds in
the 50S exit tunnel near the ribosomal protein L4 (blue) constriction
site. The peptide tail folds back over the macrolactone ring, extending
toward the P-site and A-site tRNA in the PTC. The macrolactone ring
(green) is stabilized through a hydrogen bond between A2058 and the
desosamine sugar. The peptide tail (gold) is stabilized through hydrogen
bonds with 23S rRNA C2442 and His69 of ribosomal protein L4 (blue).
The last four amino acids of the peptide tail are not seen in the
structure, and instead, their three-letter codes represent their proposed
position towards the PTC.
Binding
site of peptolide 12c in the 50S subunit of
the ribosome. Similar to TEL, peptolide 12c binds in
the 50S exit tunnel near the ribosomal protein L4 (blue) constriction
site. The peptide tail folds back over the macrolactone ring, extending
toward the P-site and A-site tRNA in the PTC. The macrolactone ring
(green) is stabilized through a hydrogen bond between A2058 and the
desosamine sugar. The peptide tail (gold) is stabilized through hydrogen
bonds with 23S rRNA C2442 and His69 of ribosomal protein L4 (blue).
The last four amino acids of the peptide tail are not seen in the
structure, and instead, their three-letter codes represent their proposed
position towards the PTC.
Conclusion
Ribosome structures have given us a molecular
understanding of the roles that specific ribosomal components play
during translation.[1−6,40,41] However, the nascent peptide exit tunnel is a ribosome component
that has yet to be fully characterized. The rRNA-lined tunnel serves
as the route of travel for nascent peptides from the PTC toward the
exterior surface of the ribosome.[7,8] Initially,
the exit tunnel was proposed to have little impact on specific nascent
chain sequences and exist solely to facilitate an unhindered passage
of peptides to the exterior of the ribosome. A growing body of research
has shown specific amino acid sequences interact with the components
of the exit tunnel, concomitantly influencing many aspects of translation
such as the translation rate, ribosome stalling and even changes in
mRNA frame maintanence.[9,13,42−44] Despite these new insights, the molecular mechanisms
used by the ribosome to identify and interact with specific nascent
peptide sequences are not well understood.Toward addressing
these deficiencies, we designed and validated a series of peptide–ketolide
(peptolide) conjugates to probe the interactions between the nascent
peptide chain and the ribosome exit tunnel. Translation inhibition
and RNA structure probing assays show that all the peptolide probes
interact with the macrolide binding pocket in the same manner as the
parent macrolide while the peptide tails of the peptolides are oriented
toward the PTC. Furthermore, we find the exit tunnel has a relaxed
preference for the directionality (N → C or C → N orientation)
of the nascent peptides. This observation suggests that the directionality
of proteins has not evolved after peptide bond formation for optimization
to transit out of the ribosome. In contrast, the overall charge of
the peptolide peptide moieties has the strongest influence on translation
inhibition.The location of the peptolide 12c in
the exit tunnel
in the context of a programmed 70S was determined by X-ray crystallography
to 3.6 Å. Our structural data places the ketolide macrocyclic
ring in the same place as previous structures.[22−25] While the position of the alkyl-aryl
arm extends further down the exit tunnel similar to position observed
in the D. radiodurans structure, the peptide tail,
however, folds back over the ketolide macrocyclic ring, extending
in the opposite direction back toward the PTC.In summary, these
data suggest that the peptolides disclosed therein
are viable probes for interrogating nascent peptide-exit tunnel interaction
from the PTC to the exit tunnel entrance. Ongoing effort is focused
on designing a new generation of peptolides, which would be able to
insert their peptide tails into the exit tunnel from the PTC entrance
to obtain a complete set of probes for the full length of the tunnel.
Methods
In Vitro Cell Extract Inhibition Assays
Cell free translation assays—E. coli (E. coli S30 Extract System for
Circular DNA, Promega) and
rabbit reticulocyte whole cell extract (Rabbit Reticulocyte Lysate
System, Nuclease Treated, Promega)—were performed as recommended
by manufacturer.[33,34] Briefly, varying concentrations
of the compounds of interest were allowed to incubate in a solution
of rabbit reticulocyte or E. coli extract and all
amino acids for 20 min at room temperature. Following brief centrifugation,
0.95 μL luciferase control template (Promega) was added to each
tube. After gentle mixing and spin down, tubes were incubated at 37
°C for 60 min (30 °C for 90 min for eukaryotic samples).
Translation was terminated by inactivating on ice for 5 min. Upon
returning to ambient temperature, 5 μL per tube (2.5 μL
for eukaryotic samples) was delivered to a LUMITRAC 200 96-well plate.
Luminescence was immediately read following the addition of the luciferin
solution using a Molecular Devices SPECTRAmax GEMINI. IC50 values were fit by logit regression. All compounds were analyzed
in triplicate and standardized against an internal vehicle control.
Chemical Footprinting of E. coli 23S rRNA
Chemical footprinting of the E. coli 23S rRNA
was performed with dimethyl sulfate (DMS) and 1-cyclohexyl-(2-morpholinoethyl)carbodiimide
metho-p-toluene sulfonate (CMCT) according to the
following protocol:[45]
Peptolide Binding
All peptolides and the azido-macrolide
precursor were incubated at a final concentration of 150 μM
with 100 pmol E. coli 70S ribosomes (New England
Biolabs), whereas clarithromycin was incubated at a concentration
of 50 μM. Binding was performed in binding buffer (10 mM HEPES,
10 mM MgCl2, 60 mM NH4Cl) at 37 °C for
30 min.[46]
DMS Chemical Modification
DMS chemical modification
was performed on intact 70S E. coli ribosomes in
the absence and presence of bound drug. Approximately 50 μg
of intact ribosome, or ribosome-peptolide complex, in 25 μM
DMS buffer (80 mM K-HEPES, 10 mM MgCl2, 100 mM NH4Cl) was aliquoted, and to this was added 1 μL DMS Stock (880
mM DMS in abs. EtOH), and the mixture was then incubated for 10 min
at 37 °C. The reaction was terminated by the addition of 12.5
μL of DMS stop buffer (1 M Tris-HCl, 0.1 M EDTA, 1 M β-mercaptoethanol,
pH 7.5). Ethanol precipitation was followed by RNA extraction. The
RNA pellet was resuspended in 400 μL extraction buffer (0.3
M NaOAc (pH 6.5), 0.5% SDS, 5 mM EDTA (pH 8.0)) at room temperature.
This was subsequently extracted three times via addition of 400 μL
of acid phenol chloroform (pH 4.5, Invitrogen). The final RNA fraction
was ethanol precipitated and the pellet was resuspended in H2O (final concentration: 0.4 μM). Aliquots were stored at −80
°C.
CMCT Modification
CMCT chemical modification was performed
on intact 70S E. coli ribosomes in the absence and
presence of bound drug. Approximately 50 μg of intact ribosome,
or ribosome-peptolide complex, in 25 μM CMCT buffer (50 mM potassium
borate pH 8.0, 10 mM MgCl2, 100 mM NH4Cl) was
aliquoted, and to this was added 12.5 μL CMCT Stock (100 mM
CMCT in CMCT buffer), and the mixture was then incubated for 10 min
at 37 °C. The reaction was terminated by the addition of 2.5
volumes of −20 °C 95% EtOH. Subsequent ethanol precipitation
was followed by RNA extraction as described above.
Reverse Transcription
DNA primers were purchased from
Keck Biotechnology (New Haven, CT). An array of primers was initially
purchased with the intent of covering as much of the 23S rRNA strand
as possible. After footprinting analysis of all primers, the primer
yielding the most useful data, named primer 2180, has the following
sequence: 5′-GGGTGGTATTTCAAGGTCGG-3′. Primer
2180 is named as such because the 5′ G of the primer anneals
to position 2180 (E. coli numbering) of the 23S rRNA.
Primer concentration was determined by UV–vis spectroscopy
in 1 cm path length quartz cuvettes using molar extinction coefficients
determined by OligoAnalyzer (IDT).A working primer stock (2.0
μM) in H2O was made fresh for each reaction. A hybridization
buffer (225 mM K-Hepes (pH 7.0), 450 mM KCl) was used to bring primer
concentration to 1.0 μM. This primer mix (2 μL) was added
to tubes containing RNA (0.8 μmol). Annealing was proceeded
by placing tubes in a water bath at 90 °C for 1 min, and the
tubes were allowed to cool to room temperature. While cooling, a master
mix was prepared using 20 μL 5× First Strand Buffer (supplied
with RT enzyme, Invitrogen), 150 μCi dATPα35S (PerkinElmer), 6.6 μL dNTP mix (110 μL 1 mM d(T, G,
C)TP, 6 μL 1 mM dATP, 664 μL H2O), and 1 μL
each of RNasin Plus (Promega) and 100 mM dithiothreitol (DTT).Upon completion of annealing, samples were briefly centrifuged
at room temperature. Each tube received 2 μL master mix, and
the sequencing tubes received the appropriate ddNTP (1 μL, 9
μM). Added last to each tube was 200U SuperScript II reverse
transcripase (Invitrogen). Tubes were gently mixed and centrifuged
before being placed in a heating block at 55 °C for 30 min. Chase
was initiated by addition of 1 μL dNTP (100 mM) to each tube
and 1 μL appropriate ddNTP (402 mM) to sequencing tubes. Tubes
were placed back in the heating block at 55 °C for 15 min. The
reaction was terminated by the addition of precipitation buffer (75
μL, 95% ethanol, 0.3 M NaOAc pH 6.5, 4 °C) and centrifuged
for 90 min (13 200 rpm, 4 °C). The supernatant was removed
and the pellets were dried and resuspended in 10 μL loading
buffer (95% formamide, 10 mM EDTA, 0.1% xylene cyanol, 0.1% bromophenol
blue, pH 11).
Analysis of Chemical Footprinting Experiments
Samples
were analyzed by running on a 5% polyacrylamide gel in a Sequi-Gen
GT system (Bio Rad). The gel and 1× TBE buffer (100 mM Tris,
90 mM Boric Acid, and 1 mM EDTA) were brought to temperature by prerunning
at 55 W to 50 °C. Lanes were thoroughly flushed with buffer and
loaded with 1 μL of sample each. Migration occurred from 45
to 90 min at 55W and 50 °C. Gels were transferred to Whatman
paper and were fixed in 20% EtOH for 20 min. They were then dried
under vacuum for 90 min at 80 °C. Once dry, gels were exposed
onto a phosphor screen (GE Healthcare) overnight. Screens were scanned
on a Typhoon Trio+ (GE Healthcare) and digital images were analyzed
with Multi Gauge (FujiFilm).The footprinting of E.
coli 23S rRNA with primer 2180 and DMS modification in the
presence of all peptolides can be found in Figure 2. Footprinting of CMCT modified 23S rRNA with primer 2180
can be seen in Figure 3.
X-ray Crystallographic
Studies of the Thermus thermophilus 70S Ribosome
Bound to the Peptolide 12c
T. thermophilus ribosomes were purified, crystallized, and
cryoprotected and the X-ray crystal structure solved as previously
described.[3]Escherichia coli tRNAfMet and tRNAPhe were purchased from Chemical
Block. The mRNA oligonucleotide was chemically synthesized by Integrated
DNA Technology with a sequence of 5′-GGCAAGGAGGUAAAAAUGUUCAAAA-3′, where the underlined AUG
and UUC represent the P- and A-site codons, respectively. Briefly,
the programmed 70S complexes were formed using previously established
conditions with the additional step being the incubation at 37 °C
for 30 min of peptolide 12c prior to crystallization.
X-ray diffraction data were collected from four crystals for the 70S-12c complex at the Northeastern Collaborative Access Team
(NE-CAT) beamline at the Advanced Proton Source, ArgonneNational
Laboratory. Each diffraction data set was integrated and scaled using
the XDS software package.[47] The structures
were solved by molecular replacement with the PHENIX software suite[48] using an initial search model composed of the Tth 70S ribosome (PDB ID codes 2WDG, 2WDH, 2WDI, and 2WDJ) with all ligands and ions removed. An
initial round of coordinate refinement was performed using each of
the ribosomal subunits as a single rigid group. Additional rounds
of rigid and Translation, Liberation, Screw-movement (TLS) refinements
were performed using defined rigid and TLS groups comprised of the
head, body, platform, and 3′ minor domains for the 30S subunit
and the 5S rRNA, L1 arm, A-site finger, central protuberance, and
protein L9 domains for the 50S subunit. Modeling of the 12C peptolide,
tRNA, mRNA, and placement of the Mg2+ ions was performed
using Coot.[49] Iterative
rounds of model building and positional and atomic displacement parameter
(ADP) refinements were performed in PHENIX to yield a final model
with the statistics reported in Table 2(51,52). Figures were generated using PyMol.[50]
Table 2
Summary
of Crystallographic Data and
Refinementa
data collection
space group
P212121
cell dimensions
a, b, c (Å)
209.2, 443.5, 618.6
α, β, γ (deg)
90.00, 90.00, 90.00
resolution (Å)
50.0–3.6 (3.7–3.6)
Rmerge (%)
27.7 (116.9)
Rp.i.mb (%)
10.2 (47.2)
I/σI
7.6 (1.8)
completeness
(%)
98.0 (95.8)
redundancy
7.4 (6.1)
Values in parentheses
are for the
highest-resolution shell.
Values in parentheses
are for the
highest-resolution shell.
Authors: Sandra C Mwakwari; William Guerrant; Vishal Patil; Shabana I Khan; Babu L Tekwani; Zachary A Gurard-Levin; Milan Mrksich; Adegboyega K Oyelere Journal: J Med Chem Date: 2010-08-26 Impact factor: 7.446
Authors: Curtis A Thorne; Bonnie Lafleur; Michelle Lewis; Alison J Hanson; Kristin K Jernigan; David C Weaver; Kari A Huppert; Tony W Chen; Chonlarat Wichaidit; Christopher S Cselenyi; Emilios Tahinci; Kelly C Meyers; Emily Waskow; Darren Orton; Adrian Salic; Laura A Lee; David J Robbins; Stacey S Huppert; Ethan Lee Journal: J Biomol Screen Date: 2011-08-21
Authors: Steven D Pratt; Caroline A David; Candace Black-Schaefer; Peter J Dandliker; Xiaoling Xuei; Usha Warrior; David J Burns; Ping Zhong; Zhensheng Cao; Anne Y C Saiki; Claude G Lerner; Linda E Chovan; Niru B Soni; Angela M Nilius; Frank L Wagenaar; Philip J Merta; Linda M Traphagen; Bruce A Beutel Journal: J Biomol Screen Date: 2004-02
Authors: Nelli F Khabibullina; Andrey G Tereshchenkov; Ekaterina S Komarova; Egor A Syroegin; Dmitrii I Shiriaev; Alena Paleskava; Victor G Kartsev; Alexey A Bogdanov; Andrey L Konevega; Olga A Dontsova; Petr V Sergiev; Ilya A Osterman; Yury S Polikanov Journal: Antimicrob Agents Chemother Date: 2019-05-24 Impact factor: 5.191